Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda. The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Sales of Keytruda topped $8 billion for the first time in a quarter, rising 10% from the […]










